Clinical Trials
Early University of Calgary trial tests high-dose niacin as add-on treatment for glioblastoma
Raportoinut AI AI:n luoma kuva Faktatarkistettu
Researchers at the University of Calgary are studying whether high doses of vitamin B3 (niacin) can improve outcomes for patients with newly diagnosed glioblastoma when added to standard treatment. An interim analysis of 24 patients found a higher-than-expected six‑month progression‑free survival rate, though investigators stress the results are preliminary and require ongoing safety monitoring.
A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.
Raportoinut AI
A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.
Takeda Pharmaceutical has announced that its AI-assisted oral psoriasis drug zasocitinib proved safe and effective in late-stage trials. The once-daily pill outperformed placebo and the existing therapy apremilast in clearing skin for patients with moderate-to-severe plaque psoriasis. If approved, it would mark one of the first drugs discovered with artificial intelligence.
Raportoinut AI
An experimental nasal vaccine has for the first time prevented the colonization of whooping cough bacteria in humans, according to a recently published clinical trial. This breakthrough could curb the disease's spread, particularly in a year of record cases in England. The BPZE1 vaccine, developed by ILiAD Biotechnologies, reduced bacterial presence by over 97% compared to placebo.
A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.
Raportoinut AI
The U.S. Food and Drug Administration has finalized a rule requiring drug sponsors to submit diversity action plans for clinical trials. This aims to ensure better representation of underrepresented groups in medical research. The rule takes effect in 2025.
Virus injection halts pancreatic tumor growth in trial
28. toukokuuta 2026 16.21Gene-editing drug slashes bad cholesterol 62 percent in trial
25. toukokuuta 2026 16.39Study finds beta blockers offer no benefit after uncomplicated heart attacks
17. toukokuuta 2026 08.37Tenaya Therapeutics publishes RIDGE-1 data on TN-401 gene therapy
12. toukokuuta 2026 11.26Intellia reports strong phase iii results for hae treatment
22. marraskuuta 2025 02.26Stem cell therapy restores vision in AMD patients
13. marraskuuta 2025 04.09Cheap gout drug colchicine may prevent heart attacks and strokes
6. marraskuuta 2025 13.09Oral semaglutide pill yields up to 16.6% weight loss in NEJM obesity trial
22. lokakuuta 2025 20.00Wegovy provides heart benefits even with minimal weight loss
20. lokakuuta 2025 00.10New compounds halt cancer growth without damaging healthy cells